Daymark Health is featured this week for expanding its value-based oncology strategy while earning industry recognition for its leadership. Co-founder Jonathan Rhodes was named to the Association for Value-Based Cancer Care’s 40 Under 40 list for 2026, underscoring his experience in payer-provider collaboration and value-based oncology.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The honor highlights Rhodes’ central role in shaping Daymark’s strategic direction and engagement with stakeholders across the cancer care ecosystem. This external validation may bolster Daymark’s credibility with partners and support adoption of its value-based cancer care solutions.
Operationally, Daymark showcased its patient-centric culture through a staff spotlight on Rhode Island–based partner Ylse Cespedes, a certified medical assistant with pediatric oncology experience. Her work emphasizes long-term navigation and emotional support for patients, caregivers, and families, aligning with the company’s whole-journey care model.
Strategically, Daymark continues to build a multi-stakeholder platform that aligns payers, providers, and patients. The company highlighted its collaboration with Blue Cross & Blue Shield of Rhode Island and Brown University Health as an example of its “win-win-win” value-based cancer care approach, co-designed with insurers and health systems.
Daymark promoted its oncology care model at the National Healthcare Continuum Conference in Scottsdale through a Connected Care Briefing aimed at decision-makers evaluating integrated reimbursement frameworks. The company also strengthened its community oncology footprint by hosting clinicians and experts at the Community Oncology Alliance conference alongside Oncology Ventures.
To support growth, Daymark appointed Ryan Liefer as vice president of Provider Growth, bringing experience from Oak Street Health, HCSC, Walgreens Health, Stellar Health, and Sylvan Health. His mandate is to scale provider partnerships nationwide and deepen engagement across the care continuum, potentially accelerating the company’s expansion.
Collectively, the week’s developments indicate that Daymark is balancing investment in compassionate, patient-centered care with expansion of value-based partnerships and leadership capacity. These moves position the company to pursue broader adoption of its oncology model and reinforce its standing within the evolving oncology ecosystem.